Methods for ex-vivo expanding stem/progenitor cells
First Claim
Patent Images
1. A method of ex-vivo expanding stem and/or progenitor cells, while at the same time, substantially inhibiting differentiation of the stem and/or progenitor cells, the method comprising:
- (a) obtaining a population of cells comprising stem and/or progenitor cells;
(b) seeding said stem and/or progenitor cells into a bioreactor, and (c) culturing said stem and/or progenitor cells ex-vivo in said bioreactor under conditions allowing for cell proliferation and, at the same time, culturing said cells under conditions selected from the group consisting of;
(i) conditions reducing expression and/or activity of CD38 in said cells;
(ii) conditions reducing capacity of said cells in responding to signaling pathways involving CD38 in said cells;
(iii) conditions reducing capacity of said cells in responding to retinoic acid, retinoids and/or Vitamin D in said cells;
(iv) conditions reducing capacity of said cells in responding to signaling pathways involving the retinoic acid receptor, the retinoid X receptor and/or the Vitamin D receptor in said cells;
(v) conditions reducing capacity of said cells in responding to signaling pathways involving PI 3-kinase;
(vi) conditions wherein said cells are cultured in the presence of nicotinamide, a nicotinamide analog, a nicotinamide or a nicotinamide analog derivative or a nicotinamide or a nicotinamide analog metabolite;
(vii) conditions wherein said cells are cultured in the presence of a copper chelator;
(viii) conditions wherein said cells are cultured in the presence of a copper chelate;
(ix) conditions wherein said cells are cultured in the presence of a PI 3-kinase inhibitor;
thereby expanding the stem and/or progenitor cells while at the same time, substantially inhibiting differentiation of the stem and/or progenitor cells ex-vivo.
2 Assignments
0 Petitions
Accused Products
Abstract
Methods of ex-vivo expansion of fetal and/or adult progenitor, and umbilical cord blood, bone marrow or peripheral blood derived stem cells in bioreactors for bone marrow transplantation, transfusion medicine, regenerative medicine and gene therapy.
72 Citations
50 Claims
-
1. A method of ex-vivo expanding stem and/or progenitor cells, while at the same time, substantially inhibiting differentiation of the stem and/or progenitor cells, the method comprising:
-
(a) obtaining a population of cells comprising stem and/or progenitor cells;
(b) seeding said stem and/or progenitor cells into a bioreactor, and (c) culturing said stem and/or progenitor cells ex-vivo in said bioreactor under conditions allowing for cell proliferation and, at the same time, culturing said cells under conditions selected from the group consisting of;
(i) conditions reducing expression and/or activity of CD38 in said cells;
(ii) conditions reducing capacity of said cells in responding to signaling pathways involving CD38 in said cells;
(iii) conditions reducing capacity of said cells in responding to retinoic acid, retinoids and/or Vitamin D in said cells;
(iv) conditions reducing capacity of said cells in responding to signaling pathways involving the retinoic acid receptor, the retinoid X receptor and/or the Vitamin D receptor in said cells;
(v) conditions reducing capacity of said cells in responding to signaling pathways involving PI 3-kinase;
(vi) conditions wherein said cells are cultured in the presence of nicotinamide, a nicotinamide analog, a nicotinamide or a nicotinamide analog derivative or a nicotinamide or a nicotinamide analog metabolite;
(vii) conditions wherein said cells are cultured in the presence of a copper chelator;
(viii) conditions wherein said cells are cultured in the presence of a copper chelate;
(ix) conditions wherein said cells are cultured in the presence of a PI 3-kinase inhibitor;
thereby expanding the stem and/or progenitor cells while at the same time, substantially inhibiting differentiation of the stem and/or progenitor cells ex-vivo. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)
-
-
27. A method of transplanting ex-vivo expanded stem and/or progenitor cells into a recipient, the method comprising:
-
(a) obtaining a population of cells comprising stem and/or progenitor cells;
(b) seeding said stem and/or progenitor cells into a bioreactor, and (c) culturing said stem and/or progenitor cells ex-vivo in said bioreactor under conditions allowing for cell proliferation and, at the same time, culturing said cells under conditions selected from the group consisting of;
(i) conditions reducing expression and/or activity of CD38 in said cells;
(ii) conditions reducing capacity of said cells in responding to signaling pathways involving CD38 in said cells;
(iii) conditions reducing capacity of said cells in responding to retinoic acid, retinoids and/or Vitamin D in said cells;
(iv) conditions reducing capacity of said cells in responding to signaling pathways involving the retinoic acid receptor, the retinoid X receptor and/or the Vitamin D receptor in said cells;
(v) conditions reducing capacity of said cells in responding to signaling pathways involving PI 3-kinase;
(vi) conditions wherein said cells are cultured in the presence of nicotinamide, a nicotinamide analog, a nicotinamide or a nicotinamide analog derivative or a nicotinamide or a nicotinamide analog metabolite;
(vii) conditions wherein said cells are cultured in the presence of a copper chelator;
(viii) conditions wherein said cells are cultured in the presence of a copper chelate;
(ix) conditions wherein said cells are cultured in the presence of a PI 3-kinase inhibitor; and
(d) recovering said expanded stem and/or progenitor cells from said bioreactor, and (e) transplanting into said recipient said ex-vivo expanded stem and/or progenitor cells produced in steps (b)-(d). - View Dependent Claims (28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50)
-
Specification